circadian rhythm raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-31. Anything still debated is marked as such rather than presented as settled.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
In March 2024, the Japanese Ministry of Health ordered stores to remove three RYR dietary supplements (Benikoji ColesteHelp, NaishiHelp Plus Cholesterol and Natto-kinase Sarasara Tsubu) produced by Kobayashi Pharmaceutical after reports of thousands made ill. Over a hundred people between the ages of 40 and 80 were hospitalized, and five had died as of 29 March, with four of them from kidney problems. There have been more than twelve thousand cases of health problems reported by users. The company said it uses a strain that does not produce citrinin. It has found puberulic acid in the recalled products and is looking into whether the substance might be linked to the fatalities. The suspect batch was manufactured in 2023. Some analysts have placed the blame on industry deregulation, intended to boost economic growth by facilitating the approval of health products. Benikoji products such as miso paste, crackers, food coloring, and a vinegar dressing made by other companies were also recalled. Kobayashi Pharmaceutical officially discontinued production of beni koji products on 8 August 2024.
=== Individual disorders === N-Acetylglutamate synthase (NAGS) deficiency Carbamoyl phosphate synthetase (CPS) deficiency Ornithine transcarbamoylase (OTC) deficiency Citrullinemia type I (Deficiency of argininosuccinic acid synthase) Argininosuccinic aciduria (Deficiency of argininosuccinic acid lyase) Argininemia (Deficiency of arginase) Ornithine translocase (SLC25A15) deficiency All urea cycle defects, except OTC deficiency, are inherited in an autosomal recessive manner. OTC deficiency is inherited as an X-linked recessive disorder, although some females can show symptoms. Most urea cycle disorders are associated with hyperammonemia, however argininemia and some forms of argininosuccinic aciduria do not present with elevated ammonia.
The song's success benefited from appearing in the John Hughes films Sixteen Candles (1984) and Weird Science (1985) from the time period, and it would later appear in Amy Heckerling's Clueless (1995) and in the horror film Devil's Due (2014). Meanwhile, another General Public song, "Taking the Day Off" was featured in Ferris Bueller's Day Off (1986). For the follow-up album, White and Stoker were replaced by brothers Gianni and Mario Minardi on guitar and drums, respectively. Hand to Mouth was significantly less successful than their debut album, and the band dissolved soon after its release. The 1993 reissue of the album includes "Taking the Day Off" and other non-album songs and remixes. Roger and Wakeling worked on various solo projects for the next few years, before reconstituting General Public in 1994 to perform a cover version of the Staple Singers' hit "I'll Take You There" for the Threesome film soundtrack. The new General Public line-up retained only vocalists Wakeling and Roger from previous incarnations; the vocal duo was now backed by Michael Railton (keyboards), Randy Jacobs (guitars), Wayne Lothian (bass), Thomas White (drums), and Norman Jones (percussion). "I'll Take You There" was a Top 40 hit in the US and Canada and a minor hit in the UK (No. 73). Jacobs and White then left the group, and new drummer Dan Chase was brought in. The sextet released the album Rub It Better for Epic Records in 1995, recorded in the US with the aid of Jerry Harrison, the former keyboardist and guitarist for Talking Heads producing.
=== Cancer === In 2007 reports emerged in the press and via the Internet that Evangelos Michelakis and coworkers at the University of Alberta had reported that sodium dichloroacetate reduced tumors in rats and killed cancer cells in vitro. Because the drug cannot be patented, financing the broad and expensive testing required to obtain FDA approval is problematic. The US Food and Drug Administration enforces the law that prohibits the sale of substances with the suggestion that they are cancer treatments unless they have been approved by the FDA. The American Cancer Society in 2012 stated that "available evidence does not support the use of DCA for cancer treatment at this time." Physicians warned of potential problems if people attempt to try DCA outside a controlled clinical trial. One problem with attempting this is obtaining the chemical. One fraudster was sentenced to 33 months in prison for selling a white powder containing starch, but no DCA, to people with cancer. The only monitored in vivo dosage of five human patients with glioblastoma with DCA was not designed to test its efficacy against their cancer. This study was rather to see whether it could be given at a specific dosage safely without causing side effects (e.g. neuropathy). All five patients were receiving other treatments during the study.
Similar structures include the 310 helix (i + 3 → i hydrogen bonding) and the π-helix (i + 5 → i hydrogen bonding). The α-helix can be described as a 3.613 helix, since the i + 4 spacing adds three more atoms to the H-bonded loop compared to the tighter 310 helix, and on average, 3.6 amino acids are involved in one ring of α-helix. The subscripts refer to the number of atoms (including the hydrogen) in the closed loop formed by the hydrogen bond.
Sources: en.wikipedia.org
However, these central Appalachian populations are scattered and very small. Another species of great interest is the beaver (Castor canadensis), which is showing a great resurgence in numbers after its near extirpation for its pelt. This resurgence is bringing about a drastic alteration in habitat through the construction of dams and other structures throughout the mountains. Other common forest animals are the black bear (Ursus americanus), striped skunk (Mephitis mephitis), raccoon (Procyon lotor), opossum (Didelphis virginianus), woodchuck (Marmota monax), bobcat (Lynx rufus), gray fox (Urocyon cinereoargenteus), red fox (Vulpes vulpes) and in recent years, the coyote (Canis latrans), another species favored by the advent of Europeans and the extirpation of eastern and red wolves (Canis rufus). European boars (Sus scrofa) were introduced in the early 20th century. Characteristic birds of the forest are wild turkey (Meleagris gallopavo silvestris), ruffed grouse (Bonasa umbellus), mourning dove (Zenaida macroura), common raven (Corvus corax), wood duck (Aix sponsa), great horned owl (Bubo virginianus), barred owl (Strix varia), screech owl (Megascops asio), red-tailed hawk (Buteo jamaicensis), red-shouldered hawk (Buteo lineatus), and northern goshawk, as well as a great variety of "songbirds" (Passeriformes), like the warblers in particular. Of great importance are the many species of salamanders and, in particular, the lungless species (family Plethodontidae) that live in great abundance concealed by leaves and debris, on the forest floor.
== Railroad infrastructure == Thailand ranked number 78 of 108 nations (1=best, 108=worst) for railway infrastructure in 2015 according to the World Economic Forum (WEF). Other ASEAN nations were ranked: Singapore, 8; Malaysia, 13; Indonesia, 43; Vietnam, 48; Philippines, 84; Myanmar, 96; Cambodia, 100.
== Habitat == Arnebia densiflora prefers mountain areas and places with dry and sunny rocky soils. It is native to Greece and Turkey on volcanic or limestone slopes and cliffs at 750–2,600 m (2,460–8,530 ft).
== I == Indigo dye Indole Inosine Inositol Insulin Insulin-like growth factor Integral membrane protein Integrase Integrin Intein Interferon Interleukin Inulin Ionomycin Ionone Iron–sulfur cluster Isoleucine Isomerase Isoprene
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.